What is the recommended dose of ranitidine (Histamine H2-receptor antagonist) for children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ranitidine Dosing in Children

IMPORTANT NOTE: Ranitidine has been withdrawn from the U.S. market by the FDA due to NDMA contamination concerns. This information is provided for historical reference only.

Standard Oral Dosing for GERD/Peptic Ulcer Disease

For pediatric patients aged 1 month to 16 years with GERD or peptic ulcer disease, the recommended dose is 5-10 mg/kg/day divided into 2-3 doses, with a maximum of 300 mg/day. 1

Age-Specific Oral Dosing Recommendations:

  • Preterm infants: 0.5 mg/kg twice daily (1 mg/kg/day total) is sufficient to maintain gastric pH >4 2
  • Term neonates: 1.5 mg/kg three times daily (4.5 mg/kg/day total) is required for adequate acid suppression 2
  • Children 1 month to 16 years: 5-10 mg/kg/day divided into 2-3 doses 1, 3

The FDA-approved formulations include peppermint-flavored syrup and effervescent tablets, with bioavailability of approximately 48% in pediatric patients, comparable to adults 3.

Intravenous Dosing for Critically Ill Children

For critically ill children requiring stress ulcer prophylaxis, a minimum dose of 3 mg/kg/day IV is necessary, with optimal control achieved at 1.5 mg/kg IV every 6 hours (6 mg/kg/day total). 4, 5

IV Dosing Algorithm:

  • Minimum effective dose: 3 mg/kg/day divided into multiple doses 4
  • Optimal prophylactic dose: 1.5 mg/kg IV every 6 hours 5
  • Goal: Maintain gastric pH ≥4 for >80% of the dosing interval 5

Critical pitfall: Lower doses (2-4 mg/kg/day) recommended in older pediatric handbooks result in poor gastric pH control in 36% of critically ill children, with pH dropping below 4 at the end of dosing intervals 4. Doses <3 mg/kg/day led to poor control in 71% of patients compared to only 19% with doses ≥3 mg/kg/day 4.

Special Clinical Contexts

Anaphylaxis Management (Second-Line Therapy):

Ranitidine 1 mg/kg IM or IV (maximum 50 mg) is used as adjunctive therapy in anaphylaxis, always in combination with epinephrine and diphenhydramine, never alone. 1, 6, 7

  • Pediatric IM dose: 1 mg/kg (range 12.5-50 mg), maximum 50 mg 6
  • IV administration: Dilute in 20 mL D5W and administer over 5 minutes 1, 7
  • Evidence: Combination of diphenhydramine plus ranitidine is superior to diphenhydramine alone 1, 6

Dosing Considerations by Clinical Context:

Duration of acid suppression varies by dose: Doses ≥3 mg/kg maintain gastric pH >4 for 89% of time during hours 4-6 post-dose, while doses <3 mg/kg only achieve 29% 8. For sustained control beyond 6 hours, doses ≥3 mg/kg are required 8.

Important Limitations and Monitoring

  • Tachyphylaxis: Develops within 6 weeks of continuous use 1
  • Efficacy: Less effective than PPIs for healing erosive esophagitis 1
  • Dosing frequency: Requires 2-3 times daily dosing due to 6-hour acid suppression duration 1
  • Renal impairment: Dose reduction required in neonates and patients with creatinine clearance <25-35 mL/min, as elimination half-life increases from 2.5-3 hours to 4.8 hours 3
  • Neonatal considerations: Plasma clearance in neonates <1 month is considerably lower (3 mL/min/kg) than in older children or adults due to reduced renal function 3

References

Guideline

Ranitidine Dosing Guidelines for Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Intramuscular Ranitidine Dosing

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Ranitidine Administration in Special Clinical Contexts

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The Effects of Increasing Doses of Ranitidine on Gastric pH in Children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.